Syngene Lowers FY25 Revenue Guidance, Yet Yes Securities Retains 'Buy' After Q3 Results - Here's Why

Syngene yet again cut its guidance, albeit marginally from high single to single digit growth as demand recovery linked to biotech funding was delayed by nearly a quarter..NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. .Yes Securities Report.Syngene International Ltd. yet again cut its guidance, albeit marginally from high single to single digit growth as demand recovery linked to biotech funding was delayed by nearly a quarter. Management expects Q4 to be similar to Q3 though it refrained from providing any colour on FY26 outlook (to be given in Q4 call). Q3 saw traction in discovery services and CDMO led by biologic manufacturing with the former driven by initial pilot projects conversion into full-fledged contracts –a durable driver for FY26 too. We believe FY26 growth trajectory assumes renewed significance after two years of tepid performance as discovery business comes out of the shadow of poor funding environment and manufacturing gets a push from commercialization of acquired biologic asset. In lieu of +2% growth in 9m FY25 and expectation of single digit rise, we cut estimates for FY25 and FY26 thereby resetting the base for FY27. Lower FY25/26/27 estimate by 13-23% but retain Buy based on 45 times FY27 PE (earlier 40x) as we tweak target multiple to account for some optimism on growth. Our revised target price stands at Rs 1,020 with lack of revenue acceleration in FY26 being key risk to our view.Click on the attachment to read the full report:.Syngene International Lowers FY25 Revenue Guidance Amid Market Challenges.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Syngene Lowers FY25 Revenue Guidance, Yet Yes Securities Retains 'Buy' After Q3 Results - Here's Why

Syngene yet again cut its guidance, albeit marginally from high single to single digit growth as demand recovery linked to biotech funding was delayed by nearly a quarter.

NDTV Profit

NDTV Profit

Follow Us

DISCOVER US FASTER

DOWNLOAD THE APP